| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 54.4 | 12.8 |
| Profit before tax | 3.8 | -30.3 |
| Net income | 3.1 | -27.1 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +325.8% |
|---|---|
| Operating margin | -3.6% |
10-Q filed with the SEC, NASDAQ: GLUE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Monte Rosa Therapeutics, Inc.: key numbers
- Share price
- $9.07Close, Nov 17
- Market cap
- $775M
- Shares outstanding
- 85.45MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Monte Rosa Therapeutics, Inc.
All →Monte Rosa Therapeutics Financial Results
Monte Rosa Therapeutics reported Q3 2026 financial results, highlighting a cash position of $582.6 million and $87.5 million in milestone payments triggered by Novartis initiating Phase 2 studies for MRT-6160. The company also announced positive Phase 1 data for MRT-8102 in cardiovascular disease and the initiation of multiple Phase 2 clinical trials across its pipeline.
- Counterparty
- Novartis
- Term
- 3 months
“The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies.”
Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics
“We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use.”
Markus Warmuth, M.D., Chief Executive Officer of Monte Rosa Therapeutics
Monte Rosa Therapeutics Clinical Trial Data
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases. The GFORCE-1 study in 108 subjects showed 80-90% NEK7 degradation and normalization of key ASCVD pathogenic drivers with a favorable safety profile, supporting the planned initiation of multiple Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.
- Earnings call
- Oct 1, 2026, 8:00 AM ET